Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

221 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Ipilimumab: unleashing the power of the immune system through CTLA-4 blockade.
Boasberg P, Hamid O, O'Day S. Boasberg P, et al. Among authors: hamid o, o day s. Semin Oncol. 2010 Oct;37(5):440-9. doi: 10.1053/j.seminoncol.2010.09.004. Semin Oncol. 2010. PMID: 21074058 Review.
Alum with interleukin-12 augments immunity to a melanoma peptide vaccine: correlation with time to relapse in patients with resected high-risk disease.
Hamid O, Solomon JC, Scotland R, Garcia M, Sian S, Ye W, Groshen SL, Weber JS. Hamid O, et al. Clin Cancer Res. 2007 Jan 1;13(1):215-22. doi: 10.1158/1078-0432.CCR-06-1450. Clin Cancer Res. 2007. PMID: 17200357 Clinical Trial.
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
O'Day SJ, Hamid O, Urba WJ. O'Day SJ, et al. Among authors: hamid o. Cancer. 2007 Dec 15;110(12):2614-27. doi: 10.1002/cncr.23086. Cancer. 2007. PMID: 18000991 Review.
A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma.
Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ. Weber J, et al. Among authors: hamid o, o day sj. Clin Cancer Res. 2009 Sep 1;15(17):5591-8. doi: 10.1158/1078-0432.CCR-09-1024. Epub 2009 Aug 11. Clin Cancer Res. 2009. PMID: 19671877 Clinical Trial.
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Wolchok JD, et al. Among authors: o day s, hamid o. Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24. Clin Cancer Res. 2009. PMID: 19934295 Clinical Trial.
Ipilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trials.
Wolchok JD, Weber JS, Hamid O, Lebbé C, Maio M, Schadendorf D, de Pril V, Heller K, Chen TT, Ibrahim R, Hoos A, O'Day SJ. Wolchok JD, et al. Among authors: hamid o, o day sj. Cancer Immun. 2010 Oct 20;10:9. Cancer Immun. 2010. PMID: 20957980 Free PMC article. Clinical Trial.
Clinical and pharmacologic evaluation of two dose levels of intetumumab (CNTO 95) in patients with melanoma or angiosarcoma.
O'Day SJ, Pavlick AC, Albertini MR, Hamid O, Schalch H, Lang Z, Ling J, Mata M, Reddy M, Foster B. O'Day SJ, et al. Among authors: hamid o. Invest New Drugs. 2012 Jun;30(3):1074-81. doi: 10.1007/s10637-011-9639-z. Epub 2011 Feb 18. Invest New Drugs. 2012. PMID: 21331745 Clinical Trial.
Atypical clinical response patterns to ipilimumab.
Ledezma B, Binder S, Hamid O. Ledezma B, et al. Among authors: hamid o. Clin J Oncol Nurs. 2011 Aug;15(4):393-403. doi: 10.1188/11.CJON.393-403. Clin J Oncol Nurs. 2011. PMID: 21810572
Systemic treatment of metastatic melanoma: new approaches.
Hamid O, Boasberg PD, Rosenthal K, O'Day SJ. Hamid O, et al. Among authors: o day sj. J Surg Oncol. 2011 Sep;104(4):425-9. doi: 10.1002/jso.22034. J Surg Oncol. 2011. PMID: 21858838 Review.
A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma.
Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, Guida M, Hyams DM, Gómez H, Bastholt L, Chasalow SD, Berman D. Hamid O, et al. J Transl Med. 2011 Nov 28;9:204. doi: 10.1186/1479-5876-9-204. J Transl Med. 2011. PMID: 22123319 Free PMC article. Clinical Trial.
221 results
Jump to page